ABL Bio and I-Mab Biopharma ink bispecific antibody deal

By Maggie Lynch

- Last updated on GMT

(Image: Getty/designer491)
(Image: Getty/designer491)

Related tags Monoclonal antibodies Immunotherapy Immuno-oncology

ABL Bio and I-Mab Biopharma have partnered to develop bispecific antibodies for immunotherapy.

Bi-specific antibodies (BsAbs) are therapeutic molecules that have shown promise in immunotherapy​, as an alternative to conventional mAbs (monoclonal antibodies). “The benefit of bi-specific antibodies is to link the immune effector cell into the tumor or stimulate two pathways with a synergistic effort,”​ I-Mab’s Raven Lin told us.

In this collaboration, ABL’s BsAb platform will be used to further develop therapeutics. ABL will pay $2.5m (€2.2m) upfront, with the possibility of aggregate payments up to $100m for R&D, regulatory and sales-based milestone payments.

ABL will also pay tiered royalties on net sales, and the firms will share global rights to the molecules.

“This agreement covers four different BsAbs of undisclosed targets, including one global out-licensing, excluding Greater China, to ABL for all indications with a primary focus on oncology, and three other co-development programs,” ​said Lin. 

“We are at fast pace of development towards an integrated pharmaceutical company, we expect to establish more partnerships in near future to support our rapid growth and set up global footprint,” ​Lin added.

I-Mab has also completed in-licensing deals with pharmaceutical companies such as MorphoSys AG​ and Genexine​. In addition, ABL recently entered into a licensing agreement with TRIGR Therapeutics​ to work on BsAbs for oncology.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars